Insider trade

CFO sold ~$565K of UTHR shares in the open market

Traded Jun 4, 2026 · Filed Jun 6, 2026

Why it stands out

The CFO of United Therapeutics sold $565K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CFO$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$565,055

Shares × reported transaction price

Timing vs results

29 days after results of May 6, 2026, 62 days before results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+0.9%	+2.1%	−1.2%
30 days	+1.8%	+0.8%	+0.9%
90 days	−8.6%	+3.6%	−12.2%

Past results only. Not a forecast.

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
This transaction was executed in multiple trades at prices ranging from $546.52 to $547.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filed 3mo ago

Traded Jul 2 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 3mo ago

Scheduled in advanceFiled 3mo ago